View webcasts of the 3rd EORTC QOL, Symptom Research and Patient Reported Outcomes in Cancer Clinical Trials Conference held at the European Parliament on17-19 October 2012.
3rd EORTC Quality of Life, Symptom Research and Patient Reported Outcomes in Cancer Clinical Trials Conference received funding from the European Union in the framework of the Health Programme.
A new EORTC booklet for patients with cancer, Cancer Clinical Trials: All you need to know, is now available online.
The provided software implements the EORTC Scoring System and Risk Tables for Stage Ta T1 Bladder Cancer as published in the paper:
Sylvester RJ, van der Meijden APM, Oosterlinck W, Witjes JA, Bouffioux C, Denis L, Newling DWW, and Kurth KH. Predicting Recurrence and Progression in Individual Patients with Stage Ta T1 Bladder Cancer Using EORTC Risk Tables: A Combined Analysis of 2596 Patients from Seven EORTC Trials. European Urology 49: 466 - 477, 2006.
Geneva, Switzerland, 15 March 2012: The European Association for the Study of the Liver (EASL) and the European Organisation for Research and Treatment of Cancer (EORTC) today publish their first joint Clinical Practice Guidelines (CPGs) on the management of hepatocellular carcinoma (HCC) [a]. The EASL-EORTC guidelines define the use of surveillance, diagnosis and therapeutic strategies recommended for patients with HCC.
"The EORTC needs to make this biobank a reality to help patients, present and future, who suffer from cancer."
For 50 years, the European Organisation for Research and Treatment of Cancer (EORTC) has conducted and coordinated pan–European cancer clinical research and large–scale clinical trials in Europe, and many standard cancer treatments are a direct consequence of these trials...
Director General Françoise Meunier discusses the challenges faced today by clinical researchers in cancer. She outlines key changes needed in the ongoing revision of the Clinical Trials Directive – in particular, the need for a risk-based approach to trials, and for Member States to harmonise their implementation of the Directive – and she describes the essential features of a suggested new partnership between academia and industry. She also covers the role EORTC will continue to play in developing the early careers of investigators.
Radical mastectomy was once the standard treatment for most breast cancer patients, but radiotherapy offered the promise of breast conserving therapies, and twenty years ago EORTC trial 10801 showed that breast conserving surgery followed by radiotherapy had equivalent efficacy as modified radical mastectomy as a loco-regional treatment for operable breast cancer.[1] At the ten year follow-up the loco-regional recurrence rate was significantly higher for patients receiving breast-conserving therapy, 20%, than for those receiving modified
Dr. Mehtap Coskun recently joined EORTC Headquarters as the Emmanual Van Der Schueren fellow. She earned her medical degree from the Mediterranean University Medicine Faculty in Antalya, Turkey in 2006 followed by an internship in Internal Medicine and Obstetrics & Gynecology at the University of Milan, Italy. She is presently a third year Radiation Oncology Research Assistant at the Dr. Abdurrahman Yurtarslan Oncology Hospital in Ankara, Turkey.
